Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

A road map for the treatment of pediatric diffuse midline glioma.

Show less

Author information

Affiliations

  • 1. University of Michigan, Ann Arbor, MI 48109, USA.
      Authors
    • Koschmann C 1
    • Al-Holou WN 1
    • Cartaxo R 1
    • Castro MG 1
    • Clausen M 1
    • Dang D 1
    • Doherty R 1
    • Franson A 1
    • Galban S 1
    • Garton H 1
    • Ji S 1
    • Lowenstein PR 1
    • Lum J 1
    • Magge S 1
    • Marini B 1
    • Martin D 1
    • Marupudi N 1
    • Messinger D 1
    • Mody R 1
    • Morgan M 1
    • Mota M 1
    • Muraszko K 1
    • Natarajan SK 1
    • Niculcea M 1
    • Opipari V 1
    • Pai MP 1
    • Peterson E 1
    • Prensner JR 1
    • Pun M 1
    • Wadden J 1
    • Wahl D 1
    • Zhang Q 1
    • Venneti S 1
    (33 authors)
  • 2. Clinica Universidad de Navarra, Navarra, Spain.
      Authors
    • Alonso MM 2
    • Garcia Moure M 2
    • Marques JG 2
    (3 authors)
  • 3. Baylor College of Medicine, Houston, TX 77030, USA.
      Authors
    • Anastas J 3
    (1 author)
  • 4. Dana-Faber Cancer Institute, Boston, MA 02215, USA.
      Authors
    • Bandopadhayay P 4
    • Filbin M 4
    • Gowda P 4
    • Pal S 4
    (4 authors)
  • 5. Stanford University, Stanford, CA 94305, USA.
      Authors
    • Barron T 5
    • Rogawski D 5
    (2 authors)
    • Show all (28)

ORCIDs linked to this article

Cancer Cell, 30 Nov 2023, 42(1):1-5
https://doi.org/10.1016/j.ccell.2023.11.002 PMID: 38039965 

Free full text available after 08 Jan 2025

Abstract 

Recent clinical trials for H3K27-altered diffuse midline gliomas (DMGs) have shown much promise. We present a consensus roadmap and identify three major barriers: (1) refinement of experimental models to include immune and brain-specific components; (2) collaboration among researchers, clinicians, and industry to integrate patient-derived data through sharing, transparency, and regulatory considerations; and (3) streamlining clinical efforts including biopsy, CNS-drug delivery, endpoint determination, and response monitoring. We highlight the importance of comprehensive collaboration to advance the understanding, diagnostics, and therapeutics for DMGs.

Full text links 

Read article at publisher's site: https://doi.org/10.1016/j.ccell.2023.11.002

References 

Articles referenced by this article (15)

Show 5 more references (10 of 15)

Citations & impact 

Impact metrics

3
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/156955808
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/156955808

Article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Funding 

Funders who supported this work.

Brain Research UK (1)

Cancer Research UK (4)

Children with Cancer UK (4)

NCI NIH HHS (2)

NINDS NIH HHS (5)

National Institutes of Health (5)

Rosetrees Trust (2)

The Brain Tumour Charity (3)

U.S. Department of Defense (1)